Hayashi H, Mercado-Asis L B, Murayama M, Yamakita N, Yasuda K, Miura K
Third Department of Internal Medicine, Gifu University School of Medicine, Japan.
Endocrinol Jpn. 1990 Dec;37(6):875-82. doi: 10.1507/endocrj1954.37.875.
We report a 37-year old Japanese female patient with Cushing's disease who was treated with a large daily dose of bromocriptine, which resulted in the reduction of the pituitary tumor size with clinical and biochemical improvements. On admission, the pituitary tumor size detected by magnetic resonance imaging (MRI) was 12.4 x 11.1 x 6.2 mm. Both the basal plasma prolactin level and its response to TRH test were normal. The patient was treated with bromocriptine at 5 to 35 mg/day. With 35 mg daily, 24-h urinary free cortisol started to decrease and eventually became normal. Four months after initiation of treatment with the drug, there was clinical remission with normalization of suppressibility of plasma cortisol with 1 mg dexamethasone. Repeated examination of the pituitary fossa by MRI showed a marked reduction in the tumor size (6.3 x 6.2 x 2.4 mm). This is a very rare case in which treatment with bromocriptine resulted in a reduction of the pituitary tumor size as well as clinical and biochemical improvements in a patient with normoprolactinemic Cushing's disease.
我们报告了一名37岁的日本女性库欣病患者,她接受了大剂量的每日溴隐亭治疗,这导致垂体肿瘤大小缩小,并伴有临床和生化指标的改善。入院时,通过磁共振成像(MRI)检测到的垂体肿瘤大小为12.4×11.1×6.2毫米。基础血浆催乳素水平及其对促甲状腺激素释放激素(TRH)试验的反应均正常。该患者接受了每日5至35毫克的溴隐亭治疗。每日服用35毫克时,24小时尿游离皮质醇开始下降并最终恢复正常。开始使用该药物治疗四个月后,出现临床缓解,血浆皮质醇对1毫克地塞米松的抑制反应恢复正常。通过MRI对垂体窝进行的重复检查显示肿瘤大小显著减小(6.3×6.2×2.4毫米)。这是一例非常罕见的病例,溴隐亭治疗使一名催乳素水平正常的库欣病患者的垂体肿瘤大小缩小,同时伴有临床和生化指标的改善。